VistaGen Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 1, 2013, regarding events occurring on April 30, 2013. VistaGen Therapeutics, Inc. (the "Company") entered into an amendment to a Securities Purchase Agreement with Bergamo Acquisition Corp. PTE LTD ("Bergamo").
Key Financial Metrics
The filing details a scheduled equity financing rather than operational financial results. The total potential investment under the amended agreement is $44,000,000, to be issued in tranches totaling 72,000,000 shares. The filing does not provide current revenue, profit, cash flow, margins, or existing debt levels.
| Investment Date | Total Amount | Total Shares |
|---|---|---|
| On or before May 15, 2013 | $1,000,000 | 2,000,000 |
| On or before May 31, 2013 | $2,000,000 | 4,000,000 |
| On or before June 30, 2013 | $8,250,000 | 16,500,000 |
| On or before July 30, 2013 | $8,250,000 | 16,500,000 |
| On or before August 31, 2013 | $8,250,000 | 16,500,000 |
| On or before September 30, 2013 | $8,250,000 | 16,500,000 |
Material Changes
The primary material change is the amendment of the closing schedule for the investment agreement originally dated April 8, 2013. The amendment sets the first closing date on or before May 15, 2013, and the final closing date on or before September 30, 2013.
Outlook and Risks
The Company anticipates receiving capital in tranches over a five-month period. The filing notes that the description of the Amendment is qualified in its entirety by reference to the full text of the Amendment attached as Exhibit 10.1. No specific risks or contingencies regarding the funding are detailed in the summary text of this report.
Key Facts for Investor Verification
- Verify the execution of the first tranche ($1,000,000) by the May 15, 2013 deadline.
- Confirm the total dilution impact of the 72,000,000 shares if all tranches are funded.
- Review Exhibit 10.1 for specific conditions precedent required for each subsequent closing.
- Check subsequent filings to confirm if the full $44,000,000 was raised or if the agreement was terminated.